No matches
Dermatology

Persistence of AD From Childhood Into Adulthood

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert describes how AD can persist into adulthood in many children with moderate-to-severe AD and discusses the risk factors for such persistence.
Christine Bangert
MD
Christine Bangert

Related resources

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

Podcast
CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

Infographic
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

videoanimation
Explore the Global Burden of Pediatric AD (PEDISTAD)

Explore the Global Burden of Pediatric AD (PEDISTAD)

interactivity
Type 2 Inflammation Within Skin Tissue in AD

Type 2 Inflammation Within Skin Tissue in AD

expert video
IL-4 Contributes to Systemic Type 2 Inflammation in AD

IL-4 Contributes to Systemic Type 2 Inflammation in AD

expert video
Diving Below the Surface of AD: The Role of Type 2 Inflammation

Diving Below the Surface of AD: The Role of Type 2 Inflammation

expert video
Considerations for Disease Modification in AD

Considerations for Disease Modification in AD

expert video
The Role of Type 2 Inflammation in Moderate-to-Severe AD

The Role of Type 2 Inflammation in Moderate-to-Severe AD

expert video
Identification and Management of AD Uncontrolled With Topical Therapies in Children

Identification and Management of AD Uncontrolled With Topical Therapies in Children

expert video
Epidemiology and Pathophysiology of AD in Children

Epidemiology and Pathophysiology of AD in Children

expert video
Atopic Dermatitis in Children: Not Just a Skin Disease

Atopic Dermatitis in Children: Not Just a Skin Disease

expert video
Type 2 Inflammation and Its Role in Atopic Dermatitis

Type 2 Inflammation and Its Role in Atopic Dermatitis

expert video
Key Treatment Considerations for Management of Atopic Dermatitis in Children

Key Treatment Considerations for Management of Atopic Dermatitis in Children

expert video
Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD

Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD

expert video
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

expert video
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Podcast
The Role of Type 2 Inflammation in Multiple Disease Trajectories

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Infographic
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
KOL Video Interview – Dr Amy Paller

KOL Video Interview – Dr Amy Paller

expert video
KOL Video Interview – Dr Paula Luna

KOL Video Interview – Dr Paula Luna

expert video
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

expert video
Navigating Complex Definitions: Early Intervention and Disease Modification in Atopic Dermatitis

Navigating Complex Definitions: Early Intervention and Disease Modification in Atopic Dermatitis

expert video
The PEDISTAD Survey: Assessing the Burden of Atopic Dermatitis in the Global Pediatric Population

The PEDISTAD Survey: Assessing the Burden of Atopic Dermatitis in the Global Pediatric Population

Infographic
Early Intervention and Disease Modification in AD: Can We Change the Course of the Disease?

Early Intervention and Disease Modification in AD: Can We Change the Course of the Disease?

expert video
What do we mean by disease control in AD?

What do we mean by disease control in AD?

expert video

Learning objectives

  • Discuss the incidence of AD in pediatric patients and the risk factors associated with AD persistence into adulthood
Tags
symposium
MAT-GLB-2407632 - 2.0 -02/2025

About this expert

Dermatology

Christine Bangert

MD

Medical University of Vienna General Hospital, Vienna, Austria

See author’s profile
Christine Bangert

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: South AfricaChange country/region